Medigen Biotechnology (ROCO:3176) Total Liabilities : NT$3,447 Mil (As of Mar. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Medigen Biotechnology Total Liabilities?

Medigen Biotechnology's Total Liabilities for the quarter that ended in Mar. 2024 was NT$3,447 Mil.

Medigen Biotechnology's quarterly Total Liabilities increased from Sep. 2023 (NT$3,405.52 Mil) to Dec. 2023 (NT$3,530.12 Mil) but then declined from Dec. 2023 (NT$3,530.12 Mil) to Mar. 2024 (NT$3,446.84 Mil).

Medigen Biotechnology's annual Total Liabilities increased from Dec. 2021 (NT$1,773.39 Mil) to Dec. 2022 (NT$3,511.26 Mil) and increased from Dec. 2022 (NT$3,511.26 Mil) to Dec. 2023 (NT$3,530.12 Mil).

Medigen Biotechnology Total Liabilities Historical Data

The historical data trend for Medigen Biotechnology's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medigen Biotechnology Total Liabilities Chart

Medigen Biotechnology Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

2,143.53

1,652.96

1,773.39

3,511.26

3,530.12

Medigen Biotechnology Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															3,343.19	3,458.44	3,405.52	3,530.12	3,446.84

Medigen Biotechnology Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Medigen Biotechnology's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	2779.891	+	(716.632	+	24.431
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	9.162)
	=	3,530

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	8527.245	-	4997.129
	=	3,530

Medigen Biotechnology's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	2704.199	+	(709.739	+	24.509
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	8.397)
	=	3,447

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	8370.593	-	4923.749
	=	3,447

Medigen Biotechnology Total Liabilities Related Terms

Thank you for viewing the detailed overview of Medigen Biotechnology's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Medigen Biotechnology (ROCO:3176) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medigen Biotechnology Corp (ROCO:3176) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

Yuancyu Street, 14F, Building No.3,, Nangang District, Taipei, TWN, 11560

Website

https://www.medigen.com.tw

Medigen Biotechnology Corp is a biopharmaceutical company primarily engaged in new drug development, drug discovery, molecular diagnostics, vaccine, and generic drugs. The new drug development business focuses mainly on the clinical stage of drug development and includes PI-88 MUPAFOSTAT for the treatment of liver cancer and OBP-301 treatment using adenovirus targeted to cancer cells only. Drug discovery includes the development of human-native mAbs for therapeutic applications related to infectious diseases. Generic drugs include pharmaceuticals for infectious diseases (antibiotics), contraceptives, nutrition milk powder, vitamin C tablets, dermatologic agents, and eye care products.

Medigen Biotechnology (ROCO:3176) Headlines

No Headlines